Neomycin absorption following Clagett procedure for postpneumonectomy empyema.
Following a Clagett stage II procedure, significant amounts of neomycin are absorbed when concentrations of 0.25% neomycin (8.9 micrograms milliliter) are used. If higher concentrations are employed, the neomycin can achieve toxic levels (40 micrograms per milliliter), with associated renal toxicity and respiratory suppression. The peel of the empyema cavity does not prevent absorption of drugs. Therefore, when drugs are inserted into an empyema cavity, due care must be exerted to prevent drug toxicity.
D000042:Absorption; D058186:Acute Kidney Injury / Q000139:chemically induced; D004322:Drainage; D004653:Empyema / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood*; D011013:Pneumonectomy; D011183:Postoperative Complications / Q000097:blood / Q000188:drug therapy*; D011512:Proteus Infections / Q000188:drug therapy; D012131:Respiratory Insufficiency / Q000139:chemically induced; D013203:Staphylococcal Infections / Q000188:drug therapy; D007507:Therapeutic Irrigation
D009355:Neomycin